Stelios Papadopoulos Exelixis, Inc. (EXEL) insider trading activity

Stelios Papadopoulos is Director of EXELIXIS, INC.. Currently has a direct ownership of 1.29 Million shares of EXEL, which is worth approximately $58.8 Million. The most recent transaction as insider was on May 29, 2025, when has been sold 9,812 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.29M

0.77% 3M change

0.77% 12M change

Total Value Held $58.8 Million

STELIOS PAPADOPOULOS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 29 2025	BUY Grant, award, or other acquisition	-	9,812 Added 0.76%	1,289,228 Common Stock
May 15 2025	SELL Open market or private sale	$1,619,129 $44.35 p/Share	36,508 Reduced 2.77%	1,279,416 Common Stock
May 15 2025	BUY Exercise of conversion of derivative security	$735,271 $20.14 p/Share	36,508 Added 2.74%	1,295,290 Common Stock
May 31 2024	BUY Grant, award, or other acquisition	-	18,838 Added 1.45%	1,279,416 Common Stock
May 20 2024	SELL Open market or private sale	$240,177 $21.0 p/Share	11,437 Reduced 0.9%	1,260,578 Common Stock
May 20 2024	BUY Exercise of conversion of derivative security	$228,695 $19.57 p/Share	11,686 Added 0.91%	1,272,015 Common Stock
Jun 01 2023	BUY Grant, award, or other acquisition	-	20,718 Added 1.62%	1,260,329 Common Stock
May 26 2022	BUY Grant, award, or other acquisition	-	19,575 Added 1.55%	1,239,611 Common Stock
Feb 22 2022	SELL Open market or private sale	$1,653,113 $19.56 p/Share	84,515 Reduced 6.48%	1,220,036 Common Stock
May 27 2021	BUY Grant, award, or other acquisition	-	16,424 Added 1.24%	1,304,551 Common Stock
May 11 2021	SELL Open market or private sale	$519,042 $24.99 p/Share	20,770 Reduced 1.59%	1,288,127 Common Stock
May 11 2021	BUY Exercise of conversion of derivative security	$512,400 $4.27 p/Share	120,000 Added 8.49%	1,293,600 Common Stock

Also insider at

EUCRW

Eucrates Biomedical Acquisition Corp.

Director

RGLS

Regulus Therapeutics Inc. Healthcare

BIIB

BIOGEN INC. Healthcare

Director

OVID

Ovid Therapeutics Inc. Healthcare